Novo Nordisk’s Rivfloza™ gets the U.S. FDA approval for treatment of primary hyperoxaluria type 1 (PH1)
Tanu Goyal
October 2, 2023
Novo Nordisk’s RivflozaTM gets the U.S. FDA approval for treatment of primary hyperoxaluria type 1 (PH1) On 29th September, Novo Nordisk obtained approval from the U.S.